Max Healthcare Institute Ltd Q1 FY2023 Concall Summary

Key Takeaways

• Record revenue and EBITDA quarter: Q1 FY23 was the highest ever, driven by a normalized operating environment, improved payor mix, and annual price revisions.
• Payor mix shift is the core margin engine: Institutional bed share was deliberately cut from 33% to 30% QoQ, with a clear path to below 15%, a shift where 85% of the revenue uplift flows straight to EBITDA.
• ARPOB surged 28% YoY to ₹66,000: The jump reflects both the annual price increase and the displacement of lower-yielding institutional patients with cash-paying and international ones.
• Brownfield expansion is imminent and low-risk: 100 beds at Shalimar Bagh this year and 300 at Dwarka in early H1 FY24 carry higher theoretical EBITDA per bed, with breakeven expected in the first quarter.
• What to watch next quarter: The pace of institutional business reduction toward the 15% target, the ramp-up of new beds at Shalimar Bagh, and any mid-year price revision if inflation persists.

Payor Mix & Margin Levers

• Institutional business is being deliberately displaced: The bed share of lower-yielding institutional patients was reduced from 33% to 30% in a single quarter, with a stated target to bring it below 15% over the next year and a half.
• The economics of the shift are powerful: Institutional business yields 45% to 50% lower revenues than non-institutional channels, so replacing it generates 45% to 50% more revenue, with 85% of that incremental revenue flowing straight to EBITDA.
• Gurgaon proves the model: EBITDA per bed at the Gurgaon facility is ₹90 lakh+ versus ₹60 lakh for the rest of the network, precisely because institutional business there was reduced from 20% to zero and replaced by higher-paying non-institutional patients.
• This is not a trade-off with occupancy: Management frames institutional business as a filler for beds that would otherwise be idle, not as a segment that competes with non-institutional demand, so the displacement is limited only by the pace at which preferred-channel demand grows.
• Margin expansion already visible: EBITDA margin expanded to 26.6% from 24.8% QoQ despite inflation, because the payor mix improvement and price increase absorbed cost pressures.

Soi: "This business yields us 45% to 50% lower revenues, okay. And once this business is replaced by, as we are seeing, is trending also, by a non-institutional business, it will generate 45% to 50% more revenues and 85% of that comes straight to our EBITDA."

Brownfield & Greenfield Expansion

• Shalimar Bagh brownfield (100 beds): Expected to be operational this year, with a very quick ramp-up and higher theoretical EBITDA per bed because fixed indirect costs like management and senior clinicians are already absorbed by the existing hospital.
• Dwarka greenfield (300 beds): On track for early H1 FY24; management expects breakeven within the year and notes that adding 300 beds to a base of 3,500 should not materially disturb network-level numbers.
• Larger capacity addition in FY25: The next wave of significant capacity is slated for FY25, with construction at the Saket site now able to proceed after a tree transplant order was obtained.
• Asset-light development is a focus area: Management is actively pursuing tie-ups with developers and ready-to-move-in hospital setups, with quite a few conversations ongoing.

Soi: "The new capacity which comes up, okay, will have some operating leverage in it simply because, like I said, you are not going to have a lot of the costs that have already been incurred within the ₹62 lakh per bed. So that number for the additional beds should be higher theoretically."

International Medical Tourism

• Revenue back to pre-COVID levels: International patient footfalls have recovered fully, despite negligible revenue from Afghanistan, which was a key territory until FY20, because efforts were made to enter new markets and increase flow from existing ones.
• Current bed share is small with room to grow: International patients occupy 4.5% to 5% of beds, contributing 8% of overall revenue, and management sees the opportunity as very large, especially with the Government's anticipated Heal in India push.
• Overseas office network expanding: The company expects to have 20+ offices operating from various countries by the end of this financial year, supporting direct-to-fly patient acquisition.
• No forward-looking guidance on the ceiling: Management declined to quantify where international patient share could land, calling the opportunity "sky's the limit" but resisting specific numbers.

Soi: "Sky's the limit. If you are asking me for precise things, we don't give forward-looking guidance in terms of specific numbers like that. But look, I think you have a huge comparative advantage in India. With the right push and the right encouragement from the Government, literally sky's the limit as far as that."

Digital & Adjacent Businesses

• Digital channel hit a record 16% of revenue: Absolute digital revenue reached ₹232 crore in Q1 FY23, already 40% of the full FY22 digital revenue, with website traffic growing 14% QoQ to 33 lakh sessions.
• Max Lab (diagnostics) grew non-COVID revenue 50% YoY: The business added 90 channel partners in Q1, taking active clients to 850+ across 32 cities, with a team now exceeding 700 people, though management acknowledged the market is challenging and disruptive with discounting.
• Max@Home (home care) is profitable with mid-teens EBITDA margin: Revenue grew 10% QoQ and 18% YoY; the business added 13 medical rooms in Q1 and now manages 62 medical outposts across corporates, described as perhaps the only profitable home care business in the country.
• A proprietary digital app is in final rollout stages: The app aims to widen reach, engage more patients, and provide an improved experience.

Competitive Position & Market Context

• Max's Delhi network scale is dominant: Management stated that Max hospitals in Delhi is equal to the size of Apollo, Medanta, Fortis and maybe another player put together.
• Apollo's Gurgaon acquisition is dismissed as a threat: The acquired asset had been available in the market for six years and Max passed on it numerous times; management sees no real challenge from that entry.
• KKR stake sale is orderly: KKR has sold about 20% over the last six to eight months, with the stock going into long hands, and has publicly stated it is not in conversations with any strategic buyers or conglomerates.
• Q1 is typically not the strongest quarter: Price increases happen in Q1 and take time to flow through insurance contracts, yet this Q1 was strong, suggesting underlying momentum.

Soi: "Today, Max hospitals is equal to the size of perhaps Apollo, Medanta, Fortis and maybe somebody else put together."

Guidance & Commitments

Key Metrics